NeuroPace (NPCE) Net Cash Flow Growth (1y) (2021 - 2026)
NeuroPace (NPCE) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.33 Bn | 174.04 Bn | 6.27 Bn | -53.07% |
| 2 | Stryker | 128.11 Bn | 125.23 Bn | 3.81 Bn | 17.60% |
| 3 | Medtronic | 107.76 Bn | 98.54 Bn | 6.41 Bn | 10.50% |
| 4 | Boston Scientific | 67.95 Bn | 66.50 Bn | 3.61 Bn | -283.58% |
| 5 | Edwards Lifesciences | 47.64 Bn | 43.97 Bn | 1.29 Bn | -564.44% |
| 6 | GE HealthCare Technologies | 28.43 Bn | 26.14 Bn | 1.98 Bn | -394.13% |
| 7 | Dexcom | 28.31 Bn | 27.20 Bn | 750.30 Mn | -31.84% |
| 8 | Smith & Nephew | 26.77 Bn | 26.19 Bn | - | - |
| 9 | Koninklijke Philips | 25.33 Bn | 22.21 Bn | 2.07 Bn | 76.43% |
| 10 | NeuroPace | 511.82 Mn | 457.84 Mn | 18.05 Mn | -145.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -145.56% |
| Dec 31, 2025 | 154.89% |
| Sep 30, 2025 | -186.98% |
| Jun 30, 2025 | -2,176.92% |
| Mar 31, 2025 | 369.69% |
| Dec 31, 2024 | -122.56% |
| Sep 30, 2024 | 35.52% |
| Jun 30, 2024 | -116.65% |
| Mar 31, 2024 | -4,475.65% |
| Dec 31, 2023 | 846.05% |
| Sep 30, 2023 | 5,225.71% |
| Jun 30, 2023 | 159.76% |
| Mar 31, 2023 | 100.98% |
| Dec 31, 2022 | 111.90% |
| Sep 30, 2022 | 100.76% |
| Jun 30, 2022 | -110.68% |
| Mar 31, 2022 | 6.46% |
| Dec 31, 2021 | 55.50% |
| Sep 30, 2021 | -113.91% |
| Jun 30, 2021 | 2,522.66% |